Assembly Biosciences (NASDAQ:ASMB) Lifted to Buy at Zacks Investment Research

Zacks Investment Research upgraded shares of Assembly Biosciences (NASDAQ:ASMB) from a hold rating to a buy rating in a report published on Tuesday morning, Zacks.com reports. Zacks Investment Research currently has $13.00 price target on the biopharmaceutical company’s stock.

According to Zacks, “Assembly Biosciences, Inc. is a biopharmaceutical company. It develops therapies for infectious diseases and other disorders of the gastrointestinal (GI) system. Assembly’s product portfolio consists of two late stage assets: VEN 307 for relief from pain associated with anal fissures and VEN 308 for the treatment of fecal incontinence. The Company is also developing novel microbiome-based technology for targeted oral delivery of therapeutic bacteria, complex proteins, viral antigens and small molecules to treat intractable infectious diseases of the GI tract, such as C. difficile infections. Assembly Biosciences Inc., formerly known as Ventrus Biosciences, Inc., is based in New York. “

Other research analysts have also issued reports about the company. Chardan Capital reissued a hold rating and set a $30.00 price target on shares of Assembly Biosciences in a report on Wednesday, August 7th. ValuEngine raised Assembly Biosciences from a hold rating to a buy rating in a report on Thursday, August 8th. BidaskClub lowered Assembly Biosciences from a sell rating to a strong sell rating in a report on Wednesday, September 4th. Finally, William Blair reissued a buy rating on shares of Assembly Biosciences in a report on Tuesday, July 16th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the company. The stock has an average rating of Buy and a consensus price target of $32.50.

Shares of ASMB opened at $14.11 on Tuesday. The firm has a market capitalization of $362.77 million, a price-to-earnings ratio of -3.55 and a beta of 1.44. The company has a debt-to-equity ratio of 0.06, a quick ratio of 9.20 and a current ratio of 9.20. Assembly Biosciences has a one year low of $10.58 and a one year high of $38.42. The stock’s fifty day moving average is $12.21 and its 200-day moving average is $15.06.

Assembly Biosciences (NASDAQ:ASMB) last issued its quarterly earnings results on Monday, August 5th. The biopharmaceutical company reported ($0.72) EPS for the quarter, beating analysts’ consensus estimates of ($1.13) by $0.41. The company had revenue of $3.08 million for the quarter, compared to analyst estimates of $3.90 million. Assembly Biosciences had a negative return on equity of 46.33% and a negative net margin of 622.25%. Analysts forecast that Assembly Biosciences will post -3.72 EPS for the current fiscal year.

Hedge funds have recently made changes to their positions in the stock. Bank of Montreal Can boosted its stake in Assembly Biosciences by 2,084.1% during the second quarter. Bank of Montreal Can now owns 1,922 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 1,834 shares in the last quarter. Quantamental Technologies LLC boosted its stake in Assembly Biosciences by 16,941.2% during the second quarter. Quantamental Technologies LLC now owns 2,897 shares of the biopharmaceutical company’s stock valued at $39,000 after buying an additional 2,880 shares in the last quarter. Aperio Group LLC bought a new position in Assembly Biosciences during the second quarter valued at about $55,000. Tower Research Capital LLC TRC boosted its stake in Assembly Biosciences by 9,134.0% during the second quarter. Tower Research Capital LLC TRC now owns 4,340 shares of the biopharmaceutical company’s stock valued at $59,000 after buying an additional 4,293 shares in the last quarter. Finally, BNP Paribas Arbitrage SA boosted its stake in Assembly Biosciences by 87,340.0% during the first quarter. BNP Paribas Arbitrage SA now owns 4,372 shares of the biopharmaceutical company’s stock valued at $86,000 after buying an additional 4,367 shares in the last quarter. 81.94% of the stock is owned by institutional investors and hedge funds.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc operates as a clinical-stage biotechnology company in the United States. The company develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome.

Recommended Story: Systematic Risk and Investors

Get a free copy of the Zacks research report on Assembly Biosciences (ASMB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.